Upstate Active Clinical Trials
Study Title:
ACNS1831 - A Phase 3 Study of Selumetinib (IND #77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)What is the purpose of the study? (in Layman's terms, please describe the study)
TreatmentUpstate Institutional Review Board (IRB) Number:
1988697Study/Protocol ID:
ACNS1831Study Phase:
3Patient Age Group:
ChildrenPrincipal Investigator:
Melanie A ComitoWho is eligible?
≥ 2 years and ≤ 21 years with newly diagnosed or have previously diagnosed NF-1associated LGG that has not been treated with any modality other than surgery.What is involved if I participate?
- How long is the study?
until accrual is met - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
No - What tests and procedures are involved?
labs, eye assessments, imaging, neurocognitive testing
Where will the study take place?
University Hospital Pediatric Hematology/Oncology inpatient and outpatient units.Other Information:
NoneWho can I contact for more information?
Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]